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Background: To study on expressions and clinical significances of CD133 protein and CD133 mRNA in primary
lesion of gastric adenocarcinoma (GC).
Methods: Expressions of CD133 protein by immunostaining (99 cases) and CD133 mRNA by semi-quantitative
RT-PCR (31 cases) were detected in primary lesion and in noncancerous gastric mucosa tissue (NCGT). Correlations
of CD133 protein expression with clinicopathological parameters and post-operative survival were analyzed.
Relations of CD133 mRNA level with Ki-67 labeling index (LI), and lymphatic metastasis were assessed too.
Results: Brown particles indicating CD133 protein positivity occurred in some parts of tumor cells and epithelium.
Expressive percentage of CD133 protein positivity was significantly higher in subgroups with >5 cm diameter
(P = 0.041), later TNM stage (P = 0.044), severer lymph node metastasis (P = 0.017), occurrences of lymphatic invasion
(P = 0.000) and vascular invasion (P = 0.000) respectively. Severer invasion depth (P = 0.011), lymph node metastasis
occurrence (P = 0.043) and later TNM stage (P = 0.049) were the independent risk factors for CD133 protein expression.
Average brightness scale value (BSV) of CD133 mRNA was significantly higher in subgroups with >5 cm diameter
(P = 0.041), lymph node metastasis occurrence (P = 0.004) and in lower Ki-67 LI (P = 0.02). Relative analysis revealed that
BSV of CD133 mRNA related positively to metastatic lymphatic nodes ratio (P = 0.008) and metastatic lymph node
number (P = 0.009), but negatively to Ki-67 LI (P = 0.009). Survival of positive subgroup of CD 133 protein was
significantly poorer (P = 0.047). Lymph node metastasis occurrence (P = 0.042), later TNM stage (P = 0.046) and CD 133
protein positive expression (P = 0.046) were respectively the independent risk factors to survival.
Conclusion: Higher expressive level of CD133 mRNA is associated to lower Ki-67 LI and severer lymphatic
metastasis. Therefore, the expressive level of CD133 mRNA can play an appropriate role to reflect the status of
lymph node metastasis and proliferation of GC. CD133 protein expression is closely related with larger tumor, later
TNM stage, lymphtic metastasis and survival of GC.
Background
Gastric cancer is among the most common form of cancer
of the digestive system with an estimated incidence of
approximately 22000 cases in the USA for 2008 [1], and is
still one of the most common cancer-related causes of
death in the world, particularly in Asian countries [2].
Worldwide, gastric carcinoma is the third most common
form of cancer with overall 5-year survival rate of less than
20% as most patients are diagnosed late and are unsuitable
for curative surgery. With the challenge of disseminated
disease at the time of diagnosis, there is a critical need for
finding more effective ways to eradicate the cancer cells.
However, the process of cancer initiation, metastasis and
recurrence is sequential and selective, and consists of a
series of independent steps with interlinks [3-6].
Reportedly, CD133 expressing cells in glioblstoma and
colorectal cancers include, but are apparently not lim-
ited to, the small subpopulation of tumor cells termed
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tion, metastasis and recurrence [4-6], and possess the
unique self-renewal properties, the multiple differentiat-
ing potential, the proliferating aptitude and the carcino-
genesis [5,7,8]. In addition to being considered as the
tumor initiating cell population, CSCs have also been
demonstrated to resistance to chemotherapy and radio-
therapy implying that they are responsible for tumor
recurrence [9,10]. At the same time, CD133 has been
considered as a CSCs marker in many kinds of tumors
such as colorectal [5,6], brain [4,7], prostate [8], pan-
creatic [11] and gastric cancers [12].
One of the aims in this study was to investigate the
expression levels of CD133 protein and CD133 mRNA in
primary lesion of gastric adenocarcinoma (GC) and to
compare these expressive levels with clinicopathological
characteristics and survival time after curative resection.
Additionally, we explored the relation of CD133 mRNA
expression level with lymphatic vessel infiltration, lymph
node metastasis and metastatic lymph node ratio [13]
which factors reflected the status of lymphatic metastasis
demonstrated wildly as one of the main risk factors for the
prognosis. At the same time, immunostaining for Ki-67, a
kind of cellule nucleus protein, and its labeling index (LI)
were applied to assess the proliferating ability of tumor
cells with higher or lower CD133 mRNA level and the
relation of this proliferating ability of tumor cells sharing
higher or lower CD133 mRNA level were evaluated.
Methods
Patients
A total of 99 patients who underwent radical gastrectomy
(D2 or D3;R 0 or R1) for primary GC at our hospital from
July 2004 to July 2009 were registered for immunohisto-
chemical staining in this study. The median age of the
patients was 62.0 years old (range 29~83 years old) in
this group of patients. Among them, a total of 31 patients
from May 2008 to July 2009 were also assessed by semi-
quantitative RT-PCR for detecting CD133 mRNA in pri-
mary lesion and in noncancerous gastric tissue (NCGT),
which was identified by pathological observation, at > 5
cm distance adjacent to primary lesion, and by immuno-
histochemical staining for Ki-67 expression in tumor
cells. In this group of patients, the median age of the
patients was 64.0 years old (range 34~83 years old). None
of them accepted any preoperative chemotherapy or
radiotherapy. All of the cases received postoperative adju-
vant chemotherapy. The diameter of tumors was ranged
from 1 to 10 cm; median 5.0 cm. Preoperative informed
consent was obtained from each patient included in the
study in accordance with institutional guidance. Half spe-
cimen from primary lesion or NCGT was fixed in 10%
buffered formalin and embedded in paraffin. In this part
of sample, full layer of gastric wall was included for next
stainings. Three sections from each sample of primary
lesion were serially cut for HE staining, CD133 and Ki-67
immunostainings. Another half specimen, mainly from
the selected mucosa layer was used for PCR detection,
was fixed in fluid nitrogen and then stored in -80°C until
use. This study was approved by ethic committee of our
hospital before its start.
Immunohistochemical and pathological examinations
Serial tissue sections with 4 μmw e r es t a i n e df o rC D 1 3 3
(CD133/1 monoclonal antibody; 1:40 dilution, Miltenyi
Biotec GmbH, Bergisch Gladbach, Germany) by ABC
method (mouse ABC Staining System, sc-2017, Santa
Cruz Biotechnology Co, CA, USA), Ki-67 (mouse against
to human of monoclonal antibody, Changdao Biotech,
Co., Shanghai, China) by two steps method [14] and HE
section. In details for CD133 immunostaining, sections
were dewaxed, and rehydrated by sequential immersion
in xylene, graded ethanol, and water. Antigen retrieval
was done by heating the slides in microwave oven in
0.01 mmol/L citrate buffer (pH 6.0). After washing in
phosphate-buffered saline (PBS), the slides were exposed
to 10% normal blocking serum (Santa Cruz Biotechnol-
ogy, CA, USA) for 10 min to reduce the nonspecific
antibody binding Endogenous peroxidase activity was
blocked by 3% hydrogen peroxide in methanol for
30 min. Incubation with primary antibody of CD133
(50 ul, 1:40 dilution) was performed for one hour at
room temperature. And then, immunodetection was per-
formed by ABC staining system according to the produc-
tion instructions. Primary antibodies were visualized with
DAB solution (Santa Cruz Biotechnology Co, CA, USA).
Finally, slides were couterstained with haematoxylin to
show the nucleus of cells clearly. Cells with brown color
as CD133 protein expression in the gland parietes, the
cellular membrane surface and the epithelium were con-
sidered as positivity of CD133 immunostaining. Negative
controls for CD133 and Ki-67 were carried out as above
by substituting normal serum for the primary antibodies.
Sections from previously studied cases of GC known to
positive expression were used as positive controls. Posi-
tive percentage as Ki-67 LI was calculated according to
the positive cells number in 1000 counted cells number
under × 400 magnifications in 5 fields freely selected
under a light microscope [14]. All sections were observed
a n ds c o r e db yt w oi n d e p e n d e n ti n v e s t i g a t o r sb l i n dt o
each patient’s status.
RNA isolation and reverse transcriptase polymerase chain
reaction (RT-PCR)
Total RNA was extracted from 80-100 mg frozen GC
tissue treated with RNA PCR Kit (TaKaRa Biotechnol-
ogy, Tokyo, Japan) following the manufacturer suggested
protocols. Oligo dT-Adaptor Primer was used with
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Page 2 of 10AMV reverse transcriptase XL for cDNA synthesis from
500 ng of total RNA. PCR was conducted with TaKaRa
Ex Taq HS DNA polymerase in 50 μl reaction volumes.
Primers (synthesized by Sangon Technology, Shanghai,
China) used were including GAPDH (sense, 5’-ACG-
GATTTGGTCGTATTGGGCG-3’;a n t i s e n s e ,5 ’-CTCCT
GGAAGATGGTGATGG-3’)w i t hap r o d u c tl e n g t ho f
197 bp and CD133 (sense, 5’-TTACGGCACTCTT-
CACCT-3’;a n t i s e n s e ,5 ’-TATTCCACAAGCAGCAAA-
3’) with a product length of 172 bp. The reactions were
conducted for GAPDH as the internal control under the
following conditions: initial denaturing step at 95°C for
1 min, 28 cycles of 95°C for 1 min, 55°C for 1 min, 72°C
for 1 min, followed by 72°C for 10 min; For CD133:
initial denaturing step at 94°C for 2 min, 28 cycles at
94°C for 30 seconds, 51°C for 30 seconds, 72°C for 30
seconds, followed by 72°C for 10 min. according to the
manufacturer’si n s t r u c t i o nF i v eμl CD133 PCR and 2 μl
of the products amplified by MyCycler™ Thermal Cycler
(Bio-Red Laboratories, CA, USA) were separated on a
1.5% agarose gel (Gene Tech, Shanghai, China) by elec-
trophoresis apparatus (Tunon, EpS 100, Shanghai Tian-
neng Tech Co. Shanghai, China). Digital images to
e x p o s u r et h eo c c u r r e n c eo fC D 1 3 3m R N Aa saw h i t e
target strip were captured on a gel documentation
system (UNIVERSAL HOOD II, Bio-Red Laboratories,
Segrate, Milan, Italy). Imaging assessments to measure
the brightness scale value (BSV) of CD133 automatically
from the write strip and to compared the relative ratio
between CD133 strip and control strip were carried out
by Quantity One 1-D analysis software (The Discov-
eries™ Quantity One 1-D Analysis Software Version 4.5,
Bio-Red Laboratories, CA, USA.).
Clinicopathological assessments
Clinicopathological parameters included gender, age,
tumor size histological grade, invasion depth, lymph
node metastasis, TNM stage, lymphatic vessel infiltra-
tion, vascular infiltration and metastatic lymph node
ratio for CD133 protein and CD133 mRNA assessments
respectively [13,15], mainly according to UICC classifi-
cation [15]. And Ki-67 LI was also used in the evalua-
tion of CD133 mRNA expression.
Prognostic analysis
The deadline of follow-up for 99 patients was until
November 2009, and the average survival time was
26.76 ± 17.02 months. A total of 9 cases (9.1% patients)
lost in follow-up period. In this registered group, 39
cases died of the recurrence of gastric cancer, vascular
diseases of brain or heart, or complications after surgery
respectively. All patients in this group for survival
assessment were divided as positive or negative sub-
group of CD133 immunostaining.
Statistics
All statistical analyses were performed with the SPSS
software version 13.0 (SPSS, Chicago, IL, USA). The
correlations between expression of CD133 protein and
clinicopathological parameters were assessed with the
chi-squared test as a univariate analysis. Furthermore,
the multivariate analysis was carried out with Logistic
analysis for these correlations in order to explain the
more important significances of the observed para-
meters. CD133 mRNA data was expressed as means ±
SD, and statistical analysis was carried out using Stu-
dent’s t test. Relative evaluations of CD133 mRNA level
with several clinicopathological data were made by
Spearman’s rho analysis. The Kaplan-Meier method was
used to estimate survival as a function of time, and sur-
vival differences were analyzed by Log-rank test. The
Cox regression model was used for multivariate analysis
of prognostic factors. In all of the tests, a P value less
than 0.05 was considered to be statistically significant.
Results
CD133 protein expression in primary lesion
Particles sharing brown color indicated to CD133 protein
expression occurred in some parts of gland parietes, cel-
lular membrane surface of some tumor cells and some
epithelium in primary lesion, in which CD133 positive
particles mainly located in some parts of tumor cells in
the mucosa and the submucosa layers (Figure 1C and
1D). Some CD133 positive cells were identified in the
wall of crypts and in the cancerous emboli in vessel-like
structures in primary lesion (Figure 1E and 1F). No posi-
tive staining was seen in NCGT as control subgroup
(Figure 1B), which positivity rate of CD133 (0%) was sig-
nificantly lower than that in cancerous subgroup (29.3%,
29 cases/99 cases, P = 0.000).
Correlation of CD133 protein expression with
clinicopathological parameters
CD133 expression was significantly correlated with
tumor diameter of > 5 cm (P = 0.041), severer lymph
node metastasis (P = 0.017), later TNM stage (P = 0.044),
occurrences of lymphatic vessel infiltration (P = 0.000)
and vascular infiltration (P = 0.000) (Table 1). Further-
more, with the increase of invasion depth of tumor, the
expressive rate of CD133 raised obviously, but no statisti-
cal significance. However, further stratified analysis
revealed that the expressive rate of CD133 in subgroup of
T3-T4 (6.06%, 6 cases/99 cases) was significantly higher
than that in subgroup of T1-T2 (23.23%, 23 cases/99
cases, P = 0.038). The multivariate evaluation by Logistic
analysis demonstrated that invasion depth (P = 0.011),
lymph node metastasis (P = 0.043) and TNM stage (P =
0.049) were the independent risk factors for CD133 pro-
tein expression respectively (Table 2).
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Page 3 of 10Figure 1 Morphological observation on the tumor cells with CD133 protein and Ki-67 immunostainings in primary lesion.N o t e :A
showed HE staining for GC tissue (×200). B showed CD133 immunostaining for NCGT (×200). C (×200) and D (×400) showed CD133
immunostaining for GC tissue. E (×200) and F (×400) showed tumor cells with CD133 positivity in the cancerous emboli in vessel-like structure. G
(×200) and H (×200) showed the higher positive and the lower positive expressions of Ki-67 immunostaining (×200) respectively.
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The semi quantitative RT-PCR detection in 31 patients
was performed to confirm the expressions of CD133
mRNA in primary lesion (100.0%) and NCGT (16.1%, 5
cases/31 cases)(c
2 = 15.125, P =0 . 0 0 0 )( F i g u r e2 A ) .
Average BSV of CD133 mRNA was 0.3783 ± 0.1411 in
primary lesion subgroup and 0.0381 ± 0.0919 in NCGT
subgroup respectively (Z = -6.533, P = 0.000) (Figure
2B). In comparison with average BSV of CD133 mRNA
in NCGT subgroup, the increasing range of average
BSV of CD133 mRNA was up to 993% in primary lesion
subgroup.
Correlation of BSV of CD133 mRNA with
clinicopathological parameters and Ki-67 LI
B S Vo fC D 1 3 3m R N Aw a ss i g n i ficantly correlated with
tumor diameter of > 5 cm (P = 0.041) and severer lymph
node metastasis (P = 0.004)(Table 3). Relative analysis
showed the BSV of CD133 mRNA rose with the incre-
ment of either the metastatic lymph node number
Table 1 Correlation between CD133 protein expression and clinicopathological features [n(%)](n = 99 cases)
Clinicopathological parameter Grouping CD133 protein expression c
2 value P value
positive negative
Gender male 18(18.18) 51(51.52) 1.130 0.288
female 11(11.11) 19(19.19)
Age(year) ≤ 60 9(9.09) 30(30.30) 1.200 0.273
>6 0 20(20.20) 40(40.40)
Tumor diameter(cm) ≤ 5 17(17.17) 40(40.40) 4.175 0.041
>5 12(12.12) 10(10.10)
Histological grade 1 5(5.05) 16(16.16) 2.030 0.566
2 13(13.13) 27(27.27)
3 11(11.11) 27(27.27)












Lymphatic vessel infiltration positive 28(28.28) 27(27.27) 27.636 0.000
negative 1(1.01) 43(43.43)
Vascular infiltration positive 28(28.28) 15(15.15) 46.624 0.000
negative 1(1.01) 55(55.56)
Table 2 Logistic analysis on the correlation of CD 133 protein expression with clinicopathological parameters
(n = 99 cases)
Parameter B SE Wald df Sig. Exp(B) 95.0%CI for Exp(B)
Gender 0.012 0.017 0.201 1 0.328 1.003 0.972~7.873
Age(year) 0.007 0.018 0.158 1 0.691 1.007 0.875~3.125
Tumor diameter(cm) 0.209 0.123 2.908 1 0.088 1.233 1.334~8.911
Invasion depth -1.238 0.488 6.430 1 0.011 0.290 1.079~12.381
Histological grade 0.181 0.281 0.414 1 0.520 1.198 0.987~3.212
Lymph node metastasis -0.929 0.459 4.102 1 0.043 0.395 1.156~18.324
TNM stage 1.048 0.636 2.720 1 0.049 2.853 1.138~14.216
Lymphatic vessel infiltration 0.847 0.601 1.568 1 0.067 3.213 1.335~10.954
Vascular infiltration 0.760 0.662 1.317 1 0.251 2.137 0.991~6.872
Yu et al. Journal of Experimental & Clinical Cancer Research 2010, 29:141
http://www.jeccr.com/content/29/1/141
Page 5 of 10(P = 0.009) or the metastatic lymph node ratio (P =
0.008) (Figure 3A and 3B).
Positive staining of Ki-67 occurred in nuclei of tumor
cells as sharing brown color (Figure 1G). Because aver-
age LI of Ki-67 was (36.6 ± 30.5)% in 31 patients, this
value of 36.6% was applied as the bound dividing low
(51.61%, 16 cases/31 cases) and high (48.39%, 15 cases/
31 cases) subgroups of Ki-67 LI [14]. BSV of CD133
mRNA in low subgroup of Ki-67 LI (0.4364 ± 0.1398)%
was significantly higher than that in high subgroup of
Ki-67 LI (0.3164 ± 0.1174%, P = 0.020) (Table 3). With
the increment of Ki-67 LI, BSV of CD133 mRNA gradu-
ally decreased to show the negative relation (Figure 3C).
Prognostic analysis
Univariate assessment revealed that the average survival
time was (22.76 ± 13.476) months in CD133 positive
subgroup while (28.41 ± 18.078) months in negative
subgroup (P = 0.000, Figure 4). Further investigation by
multivariate analysis showed that lymph node metastasis
occurrence (P = 0.042), later stage of TNM (P = 0.046)
and CD133 positive (P = 0.046) were the independent
risk factors to survival respectively (Table 4).
Discussion
CD133/prominin-1, a pentaspan transmembrane glyco-
protein, has been initially described as a surface antigen
specially to human hematopoietic stem cells [16] and
CSCs with CD 133 positivityh a v eb e e ni m p l i c a t e di n
tumor progress as identified in tumor growth of pancreatic
[11] and colon cancers [4]. AC133, i.e. CD133, polypeptide
has a predicted size of 97 kD and contains five-transmem-
brane (5-TM) domains with an extracellular N-terminus
and a cytoplasmic C-terminus. Whereas the expression of
tetraspan (4-TM) and 7-TM molecules is well documen-
ted on mature and immature hematopoietic cells and leu-
kocytes, this 5-TM type of structure containing two large
(255-amino acid [aa] and 290-aa) extracellular loops is
unique and does not share sequence homology with any
known multi-TM family members [16]. Nowadays, CD133
presentation was found in many solid tumors such as
brain tumor [4,7], prostate [8], pancreatic [11], hepatocel-
lular [12] and colon cancers [5,6], but the specific role of
these CSCs in tumor biology, including metastasis and
recurrence, is still uncertain, especially in human GC.
Although there are different phenotypes in different kinds
of CSCs, the higher expression of CD133 as same pheno-
types has been identified in CSCs, especially in solid
tumors derived from epithelium cells of gastrointestinal
organs [5-7,12,17]. O’Brien and his team [4] identified
CD133 positive cells shared the characteristics of human
colon cancer-initiating cells, in which CD133 positive
cells were able to initiate tumor growth in minor quantity
of the cells Moreover, CSCs with CD133 positivity pos-
sessed strong carcinogenesis, cloning ability and prolife-
rating capacity as demonstrated in many experiments
[4-8,11,12,17], and were resistant to anti-cancer therapy
[10,18]. Hence, the metastasis and recurrence of cancer as
one of main factors inflecting on the prognosis has still
been hard to be overcome thoroughly until now.
Regulation and control on gene expression is partially
dependent on the transcript and the protein expression
Figure 2 Detection and distribution of semi-quantitative BSV of CD133 mRNA by RT-PCR (n = 31 cases). Note: 2A showed the detection
of semi-quantitative BSV of CD133 mRNA. A and C showed CD133 mRNA expressions in primary lesions. E and G showed CD133 mRNA
expressions in NCGT. B and D showed GAPDH mRNA expressions as an internal reference for subgroup of primary lesions. F and H showed
GAPDH mRNA expressions as an internal reference for subgroup of NCGT. 2B showed the distribution of semi-quantitative BSV of CD133 mRNA.
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Page 6 of 10appearances. As reported [6], the initiation and the pro-
liferation of colorectal cancer were based on CSCs with
CD133 positive only in minor quantity, which was also
identified not only in prostate [8], pancreatic [11] and
hepatocellular [12] cancers but also in gastric cancer
[12,19]. In this study of ours, CD133 protein positive
structures had been seen in 29.3% cases in primary lesion
of 99 patients’ group, but no CD133 positive structures
in NCGT. Simultaneously, CD133 mRNA expression had
been identified in all primary lesions of 31 patients’
group, but only 16.1% cases in NCGT of this same group.
As compared with the level of CD133 mRNA BSV in
NCGT, this value was significantly higher in primary
lesion. Additionally, CD133 expression significantly cor-
related with tumor diameter of > 5 cm, later TNM stage
and T3-T4 as stratified analysis. Furthermore, either
severer invasion depth or later TNM stage was the inde-
pendent risk factor for CD133 protein expression. There-
fore, it can be concluded from the above mentioned
results that the tumor cells with CD133 protein and
CD133 mRNA may play some important roles in the
growth and the invasion of GC in human being.
Hermann PC et al [11] demonstrated that a subpopula-
tion of migrating CSCs with both CD133 positive and
CXCR4 positive was essential for tumor metastasis of pan-
creatic adenocarcinoma. Mehra N et al [20] examined
whether RNA expressions of CD133 and CD146, a pan-
endothelial marker, were increased in the blood of cancer
patients and whether these factors correlated with patient
characteristics and were predictive factors of survival.
Their results in the peripheral blood mononuclear cells of
131 progressive cancer patients, 37 healthy volunteers, and
5 patients who received granulocyte colony-stimulating
factor showed that patients with metastatic disease had a
significant increase in CD133 mRNA (P = 0.03), specifi-
cally patients with bone metastasis (P < 0.001). In a recent
study, it had been examined whether increased levels of
expression of CD133 mRNA by semi-quantitative real-
time RT-PCR analysis in peripheral blood predicted
disease recurrence in patients with colon cancer. Their
results indicated that elevated CD133 mRNA levels pre-
dicted colon cancer recurrence as an independent factor
in Stage IV of TNM disease [21]. Similarly, the higher
level of CD133 mRNA in primary lesion occurred in
Table 3 Correlation between BSV of CD133 mRNA with clinicopathological features and Ki-67 LI [n(%)] (n = 31 cases)
Parameter Grouping n(%) Mean ± SD Test value P value
Gender male 24(77.4%) 0.3674 ± 0.1292 Z = -0.520 0.603
female 7(22.6%) 0.4156 ± 0.1829
Age(year) ≤ 60 10(32.3%) 0.3150 ± 0.1140 Z = -1.648 0.099
>6 0 21(67.7%) 0.4084 ± 0.1452
Tumor diameter (cm) ≤ 5 18(58.1%) 0.3343 ± 0.1212 Z = -2.042 0.041
>5 13(41.9%) 0.4393 ± 0.1484
Histological grade 1 3(9.7%) 0.2555 ± 0.0095 H = 3.501 0.321
2 13(41.9%) 0.3674 ± 0.1185
3 15(48.4) 0.4177 ± 0.1634
Invasion depth T1 1(3.2%) 0.2630 ± 0.0311 H = 3.142 0.370
T2 5(16.1%) 0.3199 ± 0.1855
T3 13(41.9%) 0.4234 ± 0.1511
T4 12(38.7%) 0.3634 ± 0.1073
Lymph node metastasis N0 8(25.8%) 0.2395 ± 0.0309* H = 13.583 0.004
N1 12(38.7%) 0.4418 ± 0.1617
N2 7(22.6%) 0.4258 ± 0.1052
N3 4(12.9%) 0.3824 ± 0.0782
TNM stage II 5(16.1%) 0.3179 ± 0.1862 H = 6.409 0.093
II 2(6.5%) 0.2257 ± 0.0226
III 16(51.6%) 0.3951 ± 0.1461
IV 8(25.8%) 0.4207 ± 0.0882
Lymphatic vessel infiltration positive 18(58.1%) 0.5013 ± 0.1412 Z = -2.142 0.040
negative 13(41.9%) 0.3343 ± 0.1212
Vascular infiltration positive 17(54.8%) 0.4783 ± 0.1081 Z = -2.042 0.039
negative 14(45.2%) 0.3343 ± 0.1212
Ki-67 LI Lower 16(51.6%) 0.4364 ± 0.1398 Z = -2.332 0.02
higher 15(48.4%) 0.3164 ± 0.1174
*: N0 vs N1-3;N 1-3 =N 1+N2+N3 = 0.4266 ± 0.1320.
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level was positively relevant to the increments of meta-
static lymph node ratio or metastatic lymph node number
as demonstrated in our results of this study. Additionally,
CD133 positive cells in cancerous emboli in vessel-like
structures had been observed morphologically as a first
report in our knowledge. In the immunohistochemical
investigation in this study, CD133 positive percentage in
subgroup of lymph node metastasis was significantly
higher than that in subgroup without lymph node metas-
tasis. With the increments of tumor invasion depth and
TNM stage, CD133 protein positivity rate increased. From
such results, it can be concluded that the positive expres-
sions of CD133 mRNA and CD133 protein positively
related to the lymphatic metastasis in GC, which can rea-
sonably be considered as a risk factor to lymphatic metas-
tasis and tumor invasion. Hence, the strategies aimed at
the CD133 and SDF-1/CXCR4 modulating axis, and the
molecular pathway for lymphatic metastasis may have
important clinical significances to inhibit metastasis of
CSCs.
Ki-67 is a kind of nuclear protein, which expresses in
cellular cycle of G1,S ,G 2 and M phases, but not in G0
phase. In order to probe the relation of CD133 expression
Figure 3 Relation of CD133 mRNA BSV in primary lesion with lymphatic metastasis and Ki-67 LI. Note: 3A showed relation of CD133
mRNA BSV with the number of metastatic lymph node. 3B showed relation of CD133 mRNA BSV with the ratio of metastatic lymph node. And
Figure 3C showed relation of CD133 mRNA BSV with Ki-67 LI.
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Page 8 of 10with the proliferation of tumor cells with or without
CD133 positivity, the CD133 mRNA expressive level was
applied in this study due to the rare CSCs (usually around
1%-5% of total tumor cells) with CD133 protein positivity
in tumor as common and the difficulty to identify CSCs as
immature tumor cells from matured tumor cells morpho-
logically. From current limited information indicated in
this investigation of ours, there occurred the significantly
higher expression of CD133 mRNA in subgroup with
lower Ki-67 LI in comparison with that in subgroup with
higher Ki-67 LI. Theoretically, this phenomenon observed
in our study could be elucidated as the various biological
profiles in different stage of tumor differential process or
in proliferating characterization in the early stage of carci-
nogenesis and tumor development. And this proliferating
characterization would be gradually weakened in tumor
development probably. Additionally, in some extent, this
higher expression of CD133 mRNA in subgroup with
lower Ki-67 LI could also be explained to the resistant
potential of CSCs to anti-cancerous therapy because
tumor cells in Phase G0 such as most of CSCs were diffi-
cult to be killed by cytotoxin drugs and radiotherapy [18].
On the other hand, for other explanation of this interest-
ing phenomenon with negative relation between CD133
mRNA and Ki-67 LI, as our consideration, it is also con-
tributed to the different proliferating abilities of matured
tumor cells and immature tumor cells of CD133 positivity
with some characteristics of CSCs. As well known, CSCs
possessed strong differentiation proficiency, but this profi-
ciency might not mean strong proliferating ability, espe-
cially comparing with that of matured tumor cells with
CD133 negative expression probably. As there occurred so
many kinds of cells in primary lesion and the limitation of
only morphological and immunohistochemical observa-
t i o n si nt h i ss t u d y ,t h ei n v e s t i g a t i o no nt h eb o t he x p r e s -
sions of CD133 and Ki-67 in the same tumor cells should
be necessarily considered to carry out in future.
As reported, cancer patients with high CD133 mRNA
expression, using a defined cutoff value, showed a
decreased survival compared with patients with low or
undetectable CD133 expression (21% versus 45% cumu-
lative survival, respectively, after 20 months; P = 0.01).
Among patients with metastasis to the bone, cumulative
survival was only 22%, compared with 61% for patients
with low or undetectable CD133 levels (P =0 . 0 0 4 )[ 2 0 ] .
Furthermore, multivariate analysis in their study showed
that CD133 expression was an independent predictor
for overall survival in patients with bone metastases
[20]. At the same time, they compared the level of
CD146 mRNA, a pan-endothelial marker, with the level
of CD133. CD146 mRNA level was not increased in
patients with cancer, nor did CD146 mRNA level corre-
late with clinical variables or survival [20]. In this study
of ours, prognostic analysis based on the different sub-
groups with or without CD133 protein positivity was
assessed by univariate and multivariate evaluations. Uni-
variate assessment revealed that average survival time
was (22.76 ± 13.476) months in CD133 positive sub-
group while (28.41 ± 18.078) months in negative
Figure 4 Survival curves in different groups of CD133 protein
immunostaining. Note: P = 0.000 by Log rank analysis.
Table 4 Survival analysis on CD133 protein expression and clinicopathological parameters by Cox model
(n = 99 cases)
Parameter B SE Wald df Sig. Exp(B) 95.0%CI for Exp(B)
Gender 0.021 0.009 0.623 1 0.159 1.135 0.315~1.872
Age(year) 0.010 0.013 0.554 1 0.457 1.010 0.991~1.681
Tumor diameter (cm) -0.076 0.070 1.186 1 0.276 0.927 0.872~1.561
Invasion depth 0.288 0.343 0.703 1 0.402 1.334 0.318~6.105
Histological grade 0.001 0.182 0.000 1 0.994 1.001 1.169~4.669
Lymph node metastasis 0.867 0.361 0.035 1 0.042 1.978 1.987~10.238
TNM stage 0.739 0.479 0.249 1 0.046 2.187 1.889~;15.312
Lymphatic vessel infiltration 0.871 0.592 2.168 1 0.141 2.390 0.987~6.558
Vascular infiltration 0.218 0.560 0.152 1 0.697 1.244 2.377~9.912
CD133 protein expression 0.894 0.449 3.966 1 0.046 2.445 2.118~16.381
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Page 9 of 10subgroup. Multivariate analysis showed that, excepting
for lymph node metastasis occurrence and later stage of
TNM, CD133 protein positivity was also an independent
risk factor to survival. Obviously, the detection of
CD133 tumor marker regarding as one of the markers
of CSCs may be a useful and supplementary means to
take a judgment to prognosis of GC.
Conclusion
The expressions of CD133 protein and CD133 mRNA
correlated with severer lymph node metastasis and
lower LI of Ki-67. Positive expression of CD133 protein
indicated the poorer prognosis, which raised the possibi-
lity that CD133 positive cells might execute some func-
tions to promote the lymphatic metastasis in patients
with GC. However, the study about the CSCs, especially
the tumor cells with CD133 positivity, is still in the
initial stage in GC, and the biological profiles of CSCs
of gastric cancer should be further investigated in novel
diagnosis, more suitable treatment strategies including
the application of gene therapy by CD133 target and
prognostic judgment in order to improve the effect of
treatment on gastric cancer.
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